This Woman Does Not Let GNE Myopathy Control Her
Imagine living every day with fear that paralysis may be coming. The idea always lingering in the background, ominous. That’s the case for Kam Redlawsk.
WWGM’s mission is to generate awareness of GNE Myopathy among patients globally, accelerate development of a therapy for GNE Myopathy, make treatments available and accessible to all patients; and to provide support to patients for leading a fulfilling and safe life.
Here is a list of conditions this partner raises awareness and advocacy for:
Imagine living every day with fear that paralysis may be coming. The idea always lingering in the background, ominous. That’s the case for Kam Redlawsk.
Alison Laird is 42 years old, and she has GNE myopathy. The disorder causes the progressive deterioration of muscles. It eventually causes immobility. For anyone,
According to a first-person story on the Global Genes’ Rare Daily website, Tara Voogel and her family were plagued by a medical mystery for 40
For those people struggling with GNE myopathy, there is someone who wants to hear from you. Whether you’re a patient or a loved one of
Tomorrow is Rare Disease Day! There are 7,000 rare diseases and disorders that affect about 30 million Americans. Three hundred million worldwide are affected by rare
Calling all members of the GNE Myopathy community! The Neuromuscular Disease Foundation (NDF) is hosting its 5th Annual Symposium on GNE Myopathy this August 30-31st at the University
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.